MVIR-B.ST Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (15 geg. 2023 @ 18:29):

Stats
Dzisiejszy wolumen	38 387.00
Średni wolumen	28 216.00
Kapitalizacja rynkowa	402.33M
EPS	SEK0 ( 2024-04-25 )
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-5.31
ATR14	SEK0.368 (5.06%)

Wolumen Korelacja

Długi: 0.23 (neutral)

Krótki: 0.83 (strong)

Signal:(44.353) Same movement expected

Medivir AB (publ) Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Medivir AB (publ) Korelacja - Waluta/Towar

-0.60
( weak negative )

-0.85
( strong negative )

0.18
( neutral )

-0.44
( neutral )

0.27
( neutral )

0.70
( moderate )

Medivir AB (publ) Finanse

Annual	2022
Przychody:	SEK4.41M
Zysk brutto:	SEK-64.67M (-1 467.11 %)
EPS:	SEK-1.600

FY	2022
Przychody:	SEK4.41M
Zysk brutto:	SEK-64.67M (-1 467.11 %)
EPS:	SEK-1.600

FY	2021
Przychody:	SEK25.54M
Zysk brutto:	SEK0.00 (0.00 %)
EPS:	SEK-0.602

FY	2020
Przychody:	SEK13.95M
Zysk brutto:	SEK0.00 (0.00 %)
EPS:	SEK-1.437

Financial Reports:

No articles found.

Medivir AB (publ)

Medivir AB (publ) researches, develops, and sells pharmaceuticals primarily for the treatment of oncology in Sweden and internationally. The company markets Xerclear for the treatment of labial herpes under the Zoviduo name. It also develops Remetinostat for treating MF cutaneous T-cell lymphoma, as well as basal cell carcinoma. In addition, the company develops MIV-818 for the treatment of liver cancer; MIV-711 to treat osteoarthritis; and Birinapant and IGM-8444 for the treatment of solid tumors. It has a research collaboration with the Drug Discovery and Development Platform at SciLifeLab for the discovery of antivirals for SARS CoV-2; and a licensing agreement with the Tango Therapeutics for a preclinical research program, as well as Ubiquigent Limited for the preclinical research program USP7. Medivir AB (publ) was incorporated in 1987 and is based in Huddinge, Sweden.